NCT00721331View on ClinicalTrials.gov

A Phase I Study to Assess the Safety and Tolerability of Topical CRx-197 Formulations in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions
Atopic Dermatitis
Interventions
DRUG

nortriptyline HCl + loratadine

Topical

DRUG

nortriptyline HCl + loratadine

Topical

DRUG

nortriptyline HCl

Topical

DRUG

mometasone furoate

Topical

DRUG

Active ingredient free vehicle cream of CRx-197

Topical

Trial Locations (1)

Unknown

PROINNOVERA GmbH, Münster

Sponsors

Lead Sponsor

Zalicus
All Listed Sponsors
lead

Zalicus

INDUSTRY

NCT00721331 - A Phase I Study to Assess the Safety and Tolerability of Topical CRx-197 Formulations in Healthy Volunteers | Biotech Hunter | Biotech Hunter